Strides Pharma Science has sold a majority stake in its subsidiary, Pivot Path, to an Ascent Capital-led investor consortium for INR 100 crore, alongside a fresh INR 50 crore capital infusion that will support the company's expansion as an independent life sciences and digital transformation services provider.
Pivot Path | 29/06/2026 | By News Bureau
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy